Fidelity Management & Research Company led a $110m Series B round in T-knife Therapeutics, a next-generation T-cell receptor company developing a pipeline of innovative therapeutics for solid tumor patients, with participation from LSP, Qatar Investment Authority, Casdin Capital, Sixty Degree Capital, CaaS Capital, RA Capital Management, Versant Ventures and Andera Partners. The company plans to use proceeds from the financing to expand its scientific team, increase manufacturing capacity and advance its pipeline of T-cell receptor engineered T cell therapies.